190 related articles for article (PubMed ID: 25059102)
1. Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice.
Ruffini PA; Os A; Dolcetti R; Tjønnfjord GE; Munthe LA; Bogen B
J Transl Med; 2014 Jul; 12():207. PubMed ID: 25059102
[TBL] [Abstract][Full Text] [Related]
2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
3. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B
Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794
[TBL] [Abstract][Full Text] [Related]
4. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
5. [The experimental study on idiotypic DNA vaccine against human B-cell lymphoma to induce antitumor immune response].
Zhong KL; Zhang WJ; Yuan Y; Wu Y; Zhang MW; Mao N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):609-15. PubMed ID: 14706145
[TBL] [Abstract][Full Text] [Related]
6. Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.
Forconi F; King CA; Sahota SS; Kennaway CK; Russell NH; Stevenson FK
Immunology; 2002 Sep; 107(1):39-45. PubMed ID: 12225361
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
8. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.
Spellerberg MB; Zhu D; Thompsett A; King CA; Hamblin TJ; Stevenson FK
J Immunol; 1997 Aug; 159(4):1885-92. PubMed ID: 9257853
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
10. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences.
Fredriksen AB; Bogen B
Blood; 2007 Sep; 110(6):1797-805. PubMed ID: 17540847
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
12. Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.
Weiner GJ; Kaminski MS
J Immunol; 1990 Mar; 144(6):2436-45. PubMed ID: 1690244
[TBL] [Abstract][Full Text] [Related]
13. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma.
Ruffini PA; Di Nicola M; Carlo-Stella C; Siena S; Gianni AM
Curr Gene Ther; 2005 Oct; 5(5):511-21. PubMed ID: 16250891
[TBL] [Abstract][Full Text] [Related]
14. Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
Rovida A; Maccalli C; Scarfò L; Dellabona P; Stamatopoulos K; Ghia P
Clin Cancer Res; 2021 Feb; 27(3):729-739. PubMed ID: 33051305
[TBL] [Abstract][Full Text] [Related]
15. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model.
Rinaldi M; Fioretti D; Iurescia S; Signori E; Pierimarchi P; Seripa D; Tonon G; Fazio VM
Biochem Biophys Res Commun; 2008 May; 370(2):279-84. PubMed ID: 18364239
[TBL] [Abstract][Full Text] [Related]
17. [The experimental study on the idiotypic nucleic Acid vaccine constructed from the genomic DNA to lymphoma].
Lin NJ; Zhu P; Zhang YP; Shi YJ; Zhang X; Bu DF; Dong YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Apr; 10(2):126-30. PubMed ID: 12513814
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
Pai Kasturi S; Qin H; Thomson KS; El-Bereir S; Cha SC; Neelapu S; Kwak LW; Roy K
J Control Release; 2006 Jul; 113(3):261-70. PubMed ID: 16793161
[TBL] [Abstract][Full Text] [Related]
19. B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity.
Selmayr M; Menzel H; Kremer JP; Thierfelder S; Mocikat R
Cancer Gene Ther; 2000 Mar; 7(3):501-6. PubMed ID: 10766357
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
Savelyeva N; King CA; Vitetta ES; Stevenson FK
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
